GLP1_NEW
Liraglutide plus canagliflozin 1.8 to 300 mg injection once daily
CANALIRA_SC_1p8-300MG_QD
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 1.43 (0.23 to 8.90) | 0.49 |
| Type 2 diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 0.25 (0.00 to 7.54) | 0.73 |
| Type 2 diabetes (adults) | Nausea | longest follow-up | Placebo | HR 3.33 (1.13 to 9.38) | 0.41 |
| Type 2 diabetes (adults) | Constipation | longest follow-up | Placebo | HR 3.47 (0.87 to 13.23) | 0.25 |